ATE542805T1 - Ppar-delta aktivatoren - Google Patents
Ppar-delta aktivatorenInfo
- Publication number
- ATE542805T1 ATE542805T1 AT01955606T AT01955606T ATE542805T1 AT E542805 T1 ATE542805 T1 AT E542805T1 AT 01955606 T AT01955606 T AT 01955606T AT 01955606 T AT01955606 T AT 01955606T AT E542805 T1 ATE542805 T1 AT E542805T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- oxygen
- ppar
- free valency
- delta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000243596 | 2000-08-11 | ||
| JP2000402893 | 2000-12-28 | ||
| PCT/JP2001/006836 WO2002014291A1 (en) | 2000-08-11 | 2001-08-09 | PPARδ ACTIVATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE542805T1 true ATE542805T1 (de) | 2012-02-15 |
Family
ID=26597787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01955606T ATE542805T1 (de) | 2000-08-11 | 2001-08-09 | Ppar-delta aktivatoren |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6787552B2 (de) |
| EP (1) | EP1310494B1 (de) |
| JP (1) | JP4790969B2 (de) |
| AT (1) | ATE542805T1 (de) |
| AU (1) | AU2001277723A1 (de) |
| WO (1) | WO2002014291A1 (de) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| AU2002243778A1 (en) * | 2001-02-02 | 2002-09-19 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
| US7101910B2 (en) | 2001-06-12 | 2006-09-05 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP1424330B1 (de) * | 2001-08-10 | 2011-09-28 | Nippon Chemiphar Co., Ltd. | Aktivator für den peroxisome proliferator-responsiven rezeptor delta |
| IL160845A0 (en) | 2001-09-14 | 2004-08-31 | Tularik Inc | Linked biaryl compounds |
| EP1480640B1 (de) * | 2002-02-25 | 2007-08-15 | Eli Lilly And Company | Modulatoren von peroxisome proliferator-aktivierten rezeptoren |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| KR100474202B1 (ko) * | 2002-05-04 | 2005-03-08 | 강헌중 | 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체 |
| WO2004000789A1 (en) | 2002-06-19 | 2003-12-31 | Eli Lilly And Company | Amide linker peroxisome proliferator activated receptor modulators |
| GB0214139D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| PL375700A1 (en) | 2002-09-05 | 2005-12-12 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their therapeutical use |
| AU2003261935A1 (en) * | 2002-09-06 | 2004-03-29 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| US7129268B2 (en) | 2002-10-28 | 2006-10-31 | Novo Nordisk A/S | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives |
| US20050080115A1 (en) | 2002-10-28 | 2005-04-14 | Lone Jeppesen | Novel compounds, their preparation and use |
| KR20050055790A (ko) | 2002-10-28 | 2005-06-13 | 노보 노르디스크 에이/에스 | Ｐｐａｒ 매개 질환의 치료에 유용한 신규 화합물 |
| MXPA05004402A (es) | 2002-10-28 | 2005-07-26 | Novo Nordisk As | Compuestos novedosos y su uso como moduladores de receptores activados por proliferador de peroxisoma. |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| WO2004071509A1 (ja) * | 2003-02-12 | 2004-08-26 | Nippon Chemiphar Co., Ltd. | オリゴデンドロサイト分化促進剤 |
| US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| DE10337839A1 (de) * | 2003-08-18 | 2005-03-17 | Bayer Healthcare Ag | Indolin-Derivate |
| EP1684752B1 (de) | 2003-10-31 | 2007-05-16 | Janssen Pharmaceutica N.V. | Phenoxyessigsäure-derivate als peroxisom-proliferator-aktivierte rezeptor (ppar) dual-agonisten |
| EP1734963A4 (de) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen |
| WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| ATE486055T1 (de) | 2004-05-05 | 2010-11-15 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
| EP1758883B1 (de) * | 2004-05-18 | 2011-11-02 | Schering Corporation | Substituierte 2-Chinolyloxazole geeignet als PDE4 Inhibitoren |
| PE20060315A1 (es) * | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| US7833513B2 (en) * | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| CA2599454A1 (en) * | 2005-02-28 | 2006-08-31 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator activating receptor d |
| US20090203908A1 (en) * | 2005-05-25 | 2009-08-13 | Nippon Chemiphar Co., Ltd. | Activator for Peroxisome Proliferator-Activated Receptor |
| ES2449618T3 (es) | 2005-06-30 | 2014-03-20 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de PPAR-delta |
| RU2008108221A (ru) * | 2005-09-07 | 2009-10-20 | Плекссикон, Инк. (Us) | Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом) |
| ES2386734T3 (es) | 2005-12-22 | 2012-08-28 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de PPAR-DELTA |
| JP2009529512A (ja) | 2006-03-09 | 2009-08-20 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 新規な化合物、それらの製造法、及び使用法 |
| PT2014652E (pt) | 2006-04-18 | 2014-11-12 | Nippon Chemiphar Co | Agente de ativação para o recetor ativado por proliferador de peroxissoma |
| WO2008035359A2 (en) * | 2006-06-12 | 2008-03-27 | Cadila Healthcare Limited | Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives |
| US20080004281A1 (en) * | 2006-06-28 | 2008-01-03 | Kalypsys, Inc. | Methods for the modulation of crp by the selective modulation of ppar delta |
| TWI315304B (en) * | 2006-08-31 | 2009-10-01 | Univ Taipei Medical | Indoline-sulfonamides compounds |
| JP5864077B2 (ja) | 2006-09-08 | 2016-02-17 | ロード アイランド ホスピタル | アルコール誘発性肝疾患の治療、予防および回復 |
| AU2007292883B2 (en) | 2006-09-08 | 2013-09-05 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
| KR20090064458A (ko) | 2006-10-20 | 2009-06-18 | 머크 앤드 캄파니 인코포레이티드 | 봄베신 수용체 아형-3 조절제로서의 치환된 이미다졸 |
| CA2664794A1 (en) | 2006-10-20 | 2008-05-02 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| US8183275B2 (en) | 2006-10-20 | 2012-05-22 | Merck Sharp & Dohme Corp. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| FR2910893A1 (fr) * | 2006-12-29 | 2008-07-04 | Genfit Sa | Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazolyl)-phenyl-propan-1-one substitues, preparations et utilisations. |
| PT2277874T (pt) | 2008-04-15 | 2018-08-10 | Nippon Chemiphar Co | Ativador para recetor ativado por proliferador de peroxissoma |
| ES2712052T3 (es) | 2008-10-17 | 2019-05-09 | Cymabay Therapeutics Inc | Métodos para reducir partículas de LDL pequeñas y densas |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| EP2380884B1 (de) * | 2008-12-01 | 2014-02-12 | Mitsubishi Tanabe Pharma Corporation | Carbonsäurederivat mit thiazolring und dessen pharmazeutische verwendung |
| JP2013501812A (ja) | 2009-08-14 | 2013-01-17 | セレニス セラピューティクス ホールディング エス．エー． | 炎症またはエネルギー代謝／産生関連疾患の治療または予防のためのＰＰＡＲδリガンドの使用 |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EA025199B1 (ru) * | 2010-12-28 | 2016-11-30 | Кадила Хелзкэр Лимитед | Гетероциклические соединения, подходящие для лечения дислипидемии |
| EA201690035A1 (ru) | 2011-02-25 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов |
| EP2832729A4 (de) * | 2012-03-29 | 2015-08-05 | Shionogi & Co | N-phenyl-n'-phenylsulfonylpiperazinderivat und verfahren zur herstellung eines zwischenprodukts dafür |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
| EP2970119B1 (de) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Neuartige indolderivate als antidiabetika |
| PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
| EP3016951B1 (de) | 2013-07-02 | 2017-05-31 | Bristol-Myers Squibb Company | Tricyclische pyrido-carboxamid-derivate als rock inhibitoren |
| EP3016950B1 (de) | 2013-07-02 | 2017-06-07 | Bristol-Myers Squibb Company | Tricyclische pyrido-carboxamid-derivate als rock inhibitoren |
| ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2021109549A (ru) | 2014-08-29 | 2021-05-13 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ |
| WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| KR102708050B1 (ko) | 2018-01-31 | 2024-09-24 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
| CN113302189A (zh) | 2018-11-20 | 2021-08-24 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
| RU2714672C1 (ru) * | 2019-02-04 | 2020-02-19 | Федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский государственный университет аэрокосмического приборостроения" | Устройство для определения параметров движения цели |
| AU2020329956B2 (en) | 2019-08-12 | 2023-11-16 | Deciphera Pharmaceuticals, Llc. | Ripretinib for treating gastrointestinal stromal tumors |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| JP7534416B2 (ja) | 2019-12-30 | 2024-08-14 | デシフェラ・ファーマシューティカルズ，エルエルシー | １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物 |
| JP2023509629A (ja) | 2019-12-30 | 2023-03-09 | デシフェラ・ファーマシューティカルズ，エルエルシー | 非晶質キナーゼ阻害剤の製剤およびその使用方法 |
| WO2022189856A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2320387A1 (de) * | 1973-04-21 | 1974-10-31 | Boehringer Mannheim Gmbh | Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben |
| US5262540A (en) * | 1989-12-20 | 1993-11-16 | Bristol-Myers Squibb Company | [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters |
| GB9027023D0 (en) * | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
| CA2090283A1 (en) * | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
| WO1997028115A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
| EP1023907B1 (de) | 1997-07-24 | 2009-01-21 | Astellas Pharma Inc. | Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung |
| JP4345230B2 (ja) * | 1998-03-10 | 2009-10-14 | 小野薬品工業株式会社 | カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤 |
| PL344002A1 (en) * | 1998-05-11 | 2001-09-10 | Takeda Chemical Industries Ltd | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
| US6589969B1 (en) * | 1998-10-16 | 2003-07-08 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| CA2382966A1 (en) | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
-
2001
- 2001-08-09 AT AT01955606T patent/ATE542805T1/de active
- 2001-08-09 JP JP2002519434A patent/JP4790969B2/ja not_active Expired - Lifetime
- 2001-08-09 WO PCT/JP2001/006836 patent/WO2002014291A1/ja active Application Filing
- 2001-08-09 AU AU2001277723A patent/AU2001277723A1/en not_active Abandoned
- 2001-08-09 US US10/344,496 patent/US6787552B2/en not_active Expired - Lifetime
- 2001-08-09 EP EP01955606A patent/EP1310494B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20040097739A1 (en) | 2004-05-20 |
| EP1310494A1 (de) | 2003-05-14 |
| US6787552B2 (en) | 2004-09-07 |
| WO2002014291A1 (en) | 2002-02-21 |
| EP1310494A4 (de) | 2004-10-20 |
| JP4790969B2 (ja) | 2011-10-12 |
| EP1310494B1 (de) | 2012-01-25 |
| AU2001277723A1 (en) | 2002-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE542805T1 (de) | Ppar-delta aktivatoren | |
| DK1424330T3 (da) | Aktivator for peroxisom proliferator-responsiv receptor delta | |
| DK1445258T3 (da) | Aktivator for peroxisomproliferator-aktiveret receptor delta | |
| NO951398D0 (no) | Heterosykliske forbindelser med anti-diabetisk aktivitet, deres fremstilling og bruk | |
| ATE282614T1 (de) | Phenylharnstoff und phenylthioharnstoffderivate | |
| DE69331414D1 (de) | Depsipeptide, herstellung und anwendung | |
| CY1109863T1 (el) | Παραγωγα θειαζολης για χρηση ως αντιφλεγμονωδη | |
| ID17851A (id) | Persenyawaan heterosiklis, produksi dan pemakaiannya | |
| MY149463A (en) | Novel compounds | |
| IL147651A0 (en) | Isoxazoline derivative and herbicide containing the same as the active ingredient | |
| DK283589D0 (da) | 1-indolylalkyl-4-(substitueret pyridinyl)-piperaziner | |
| DK1447400T3 (da) | Bicyklisk forbindelse | |
| FI923033A (fi) | N-fenyltioureaderivat och farmaceutisk anvaendning | |
| CO4910146A1 (es) | Dihidropironas con actividad antiviral mejorada | |
| DK0387489T3 (da) | Anvendelse af 2,2,6,6-tetramethyl-4-aminopiperidinamider som fungicider | |
| ATE137759T1 (de) | S'-adenosyl-methionin-decarboxylase-inhibitoren | |
| ATE163649T1 (de) | Peptide, herstellung und deren verwendung | |
| TW200626007A (en) | Material for electroluminescent element and electroluminescent element | |
| DK0413278T3 (da) | Anvendelse af xanthinderivater mod mavesår | |
| KR890003669A (ko) | 제초 활성 페녹시알칸카복실산 유도체 | |
| TH20624A (th) | อนุพันธ์แอซิลของแอโซโลน |